drug
Desowen
Marketedupdated 5mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
indications
investigational
Psoriasis
all catalysts(0)
nothing on the calendar yet
Trials studying Desowen
- phase3A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
- phase1Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
- phase3Budesonide/Formoterol Inhalation Powder in Adults With Asthma
- phase4A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
- phase3A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
- phase3Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
- phase4Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
- phase2Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 13, 2027
314 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Aug 13, 2027formulationUS 8460641314d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that